Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond

Purpose of Review Hypertension is the leading modifiable cardiovascular risk factor in the United States, with racially/ethnically diverse populations experiencing a disproportionate burden, associated with social, structural, and potentially biological determinants. This review examines how recently approved and investigational pharmacologic therapies and device-based interventions may advance hypertension control in 2026 and beyond, with deliberate attention to the strength and applicability of the available evidence in racially/ ethnically diverse populations. Recent Findings Aldosterone synthesis and mineralocorticoid receptor signaling represent important advances beyond the present guidelines for resistant hypertension and cardiovascular-kidney-metabolic risk reduction. For instance, baxdrostat, a recently approved aldosterone synthase inhibitor (ASI), has demonstrated clinically meaningful blood pressure reductions. In addition, lorundrostat, an investigational ASI, provides a model for racially representative trial design through the intentional enrollment of Black and Hispanic/Latino participants and consistent efficacy across racial subgroups. In contrast, pivotal finerenone trials demonstrated improved cardiac and renal outcomes but included limited representation of Black adults. Additional approved therapies include an agent targeting the endothelin pathway, aprocitentan, and device-based interventions via renal denervation therapy, although their effectiveness in diverse populations remains unknown. Therapies targeting natriuretic peptide signaling remain investigational but could potentially expand the therapeutic landscape. Summary Advances in antihypertensive therapy offer new opportunities to improve blood pressure control and reduce cardiovascular risk beyond the 2025 American Heart Association (AHA) and American College of Cardiology (ACC) AHA/ACC High Blood Pressure Guideline-directed approach. Ensuring equitable benefit from these innovations requires that therapeutic innovation be coupled with deliberate efforts to ensure equitable delivery and benefit across populations.

Authors

Publication Details

Journal
Current Hypertension Reports
Published
2026-11-20
DOI
https://doi.org/10.1007/s11906-026-01403-5
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond

Onyedika John Ilonze, Keith C. Ferdinand, Modele O. Ogunniyi, Chinenye Cynthia Odo et al.
Current Hypertension Reports
Blood Pressure and Hypertension Studies
article

Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond

Onyedika John Ilonze, Keith C. Ferdinand, Modele O. Ogunniyi, Chinenye Cynthia Odo, Tina Reddy
article en

Abstract

Purpose of Review Hypertension is the leading modifiable cardiovascular risk factor in the United States, with racially/ethnically diverse populations experiencing a disproportionate burden, associated with social, structural, and potentially biological determinants. This review examines how recently approved and investigational pharmacologic therapies and device-based interventions may advance hypertension control in 2026 and beyond, with deliberate attention to the strength and applicability of the available evidence in racially/ ethnically diverse populations. Recent Findings Aldosterone synthesis and mineralocorticoid receptor signaling represent important advances beyond the present guidelines for resistant hypertension and cardiovascular-kidney-metabolic risk reduction. For instance, baxdrostat, a recently approved aldosterone synthase inhibitor (ASI), has demonstrated clinically meaningful blood pressure reductions. In addition, lorundrostat, an investigational ASI, provides a model for racially representative trial design through the intentional enrollment of Black and Hispanic/Latino participants and consistent efficacy across racial subgroups. In contrast, pivotal finerenone trials demonstrated improved cardiac and renal outcomes but included limited representation of Black adults. Additional approved therapies include an agent targeting the endothelin pathway, aprocitentan, and device-based interventions via renal denervation therapy, although their effectiveness in diverse populations remains unknown. Therapies targeting natriuretic peptide signaling remain investigational but could potentially expand the therapeutic landscape. Summary Advances in antihypertensive therapy offer new opportunities to improve blood pressure control and reduce cardiovascular risk beyond the 2025 American Heart Association (AHA) and American College of Cardiology (ACC) AHA/ACC High Blood Pressure Guideline-directed approach. Ensuring equitable benefit from these innovations requires that therapeutic innovation be coupled with deliberate efforts to ensure equitable delivery and benefit across populations.

Current Hypertension ReportsVol. 28(1)
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon